Spring Creek Capital’s Envoy Medical COCH Stock Holding History

Spring Creek Capital’s Portfolio COCH Stock Details COCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-500,000	Closed	-$4.89M	–	18
2022 Q1	$4.89M	Hold	500,000	–	–	0.19%	95
2021 Q4	$4.88M	Hold	500,000	–	–	0.19%	86
2021 Q3	$4.85M	Hold	500,000	–	–	0.24%	93
2021 Q2	$4.87M	Buy	+500,000	New	+$4.86M	0.24%	84

Other funds holding COCH

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

DAM

DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Spring Creek Capital's COCH Position: Q2 2022 in Review

Spring Creek Capital sold out of Envoy Medical (COCH) in Q2 2022, closing a stake of 500,000 shares — an estimated $4.89M sold.

Spring Creek Capital first reported a position in COCH in Q2 2021 and held it in 4 quarters. The position peaked at $4.89M in Q1 2022. 89 funds tracked by Wall St. Rank hold COCH as of Q2 2022.

Spring Creek Capital reported no remaining Envoy Medical position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 500,000 Envoy Medical shares in Q2 2022, an estimated $4.89M.
Spring Creek Capital first reported a position in Envoy Medical in Q2 2021 and held it in 4 quarters.
Spring Creek Capital's Envoy Medical position peaked at $4.89M in Q1 2022.
89 funds tracked by Wall St. Rank held Envoy Medical as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.